Infection by any of the four dengue virus (DENV) serotypes produces a wide spectrum of clinical illness in humans. Differences in clinical manifestation and severity have been associated with secondary heterologous infection, patient age, and virus serotype. In this context, this retrospective study sought to analyze the presentation of dengue in patients during the 2014 DENV-4 outbreak affecting the City of Orán, Salta Province, Argentina. Demographic data, clinical manifestations, and laboratory abnormalities of laboratory-confirmed dengue patients were compared between age groups and between patients with and without warning signs. Of 301 patients with laboratory-confirmed dengue, 37.9% presented dengue with warning signs. Although nearly half of all patients had secondary DENV infections, no severe dengue cases, or deaths were reported. Furthermore, no association was found between incidence of warning signs and pre-existing immunity to DENV. Pediatric patients were least likely to present warning signs and showed significantly decreased risk of fever, retro-orbital pain, arthalgia, diarrhea and thrombocytopenia, and higher risk of rash compared to older patients. Female patients of all ages were also at higher risk of developing several symptoms. The characterization of DENV-4 infection in humans, a DENV serotype recently reported in Argentina, revealed differences in clinical manifestations, laboratory parameters and the presence/absence of warning signs based on age group. Further investigation of these age-related differences should contribute to better assessment of dengue disease in at risk populations.

**KEYWORDS**
age-related differences, dengue virus, disease outcomes, epidemiology, pediatric population

1 | INTRODUCTION

Dengue virus (DENV) is a flavivirus that produces the most prevalent arthropod-borne viral disease in humans. After a lapse in the region-wide vector eradication put in place during the mid 20th century, DENV serotypes 1-4 have re-emerged in the Americas, making dengue a public health priority.1-2 DENV infection produces a wide range of clinical manifestations including both asymptomatic and clinical infection.3 The latter are grouped by the World Health Organization (WHO) into three levels of disease severity: dengue without warning signs (DWoWS), a febrile illness frequently associated with rash and joint pain; dengue with warning signs...
(DWWS), in which the patient may also experience hemorrhage, swelling, hepatomegaly, and/or an increase in hematocrit and thrombocytopenia; and the potentially fatal severe dengue (SD), which may include severe bleeding, shock, organ failure, and respiratory distress. Differences in clinical manifestations and severity have been associated with secondary heterologous DENV infection, patient age, and virus serotype, though the underlying mechanisms of disease enhancement are still not fully characterized.

Since the re-emergence of DENV in Argentina in 1998, important outbreaks have occurred in 3-5 year cycles. The majority of cases occur in Northern provinces, where the sub-tropical climate and occasional winter frosts allow for seasonal proliferation of the most common DENV vector, *Aedes aegypti*. Though *A. aegypti* flight range is extremely limited, frequent domestic and commercial contact with bordering countries in which DENV is endemic can lead to DENV importation and the autochthonous spread of the virus. The city San Ramón de la Nueva Orán (also referred to as Orán) is the head of the homonymous department; it has a population of approximately 140,000 inhabitants and it is located in the province of Salta on the Northwestern border of Argentina, 270 km Northeast of the province capital Salta, and 30 km South of Bolivia (Figure 1). Since 1998, the province of Salta has experienced outbreaks of all four DENV serotypes; DENV-2 in 1998, DENV-1 in 2002, DENV-3 in 2003 (specifically in Orán), both DENV-1 and DENV-2 between 2008 and 2014, and DENV-4 in 2013 and 2014, the latter mainly affected the Northern departments, including the Department of Orán. DENV-4 has been endemic in Central America since its introduction to the eastern Caribbean islands in 1981. In recent years, DENV-4 has been reported in increasingly southern latitudes in South America, and was reported for the first time in Argentina in 2010 in a single infection in the province of Santa Fe.

Dengue is considered a pediatric disease in endemic settings, where many adults have acquired immunity to multiple serotypes through repeated heterotypic infection. Because epidemiological studies are primarily conducted in endemic regions, studying dengue outbreaks in re-emergent, epidemic settings offers an interesting opportunity to evaluate clinical manifestations in adults and children who have had similar lifetime exposure to DENV. Furthermore, each DENV serotype represents a population of viral genotypes whose evolution may influence disease manifestation and patient prognosis. The current study describes the clinical manifestations and laboratory abnormalities of children and adults in the first autochthonous DENV-4 outbreak in Argentina.

FIGURE 1 Geographical location of the study. The city San Ramon de la Nueva Orán (Orán) is located in the province of Salta on the Northwestern border of Argentina, 270 km Northeast of the province capital Salta and 30 km South of Bolivia.
2 | MATERIALS AND METHODS

2.1 | Study population

This retrospective study was conducted at the regional public San Vicente de Paul Hospital between February and June 2014. San Vicente de Paul Hospital is the only high-complexity hospital in the Department of Orán, which provides medical assistance to the City of Orán and surrounding areas, with a catchment population of 170,000 persons. Four private clinics also offer medical care in the municipality. During DENV outbreaks, an outpatient care center is created at San Vicente de Paul Hospital to address the unique needs of patients with probable dengue infections. The study’s inclusion criteria were: (1) presentation for treatment at San Vicente de Paul Hospital’s care center with symptoms suggestive of DENV infection; (2) laboratory confirmation of DENV infection by ELISA for IgM and NS1; and (3) residence in the municipality of Orán. All of the patients included in the study were treated as outpatients. Dengue cases were defined by both the presence of IgM (PanBio Dengue IgM Capture ELISA, Standard Diagnostics INC., Yongin, Gyeonggi, Republic of Korea) and NS1 antigen (Platelia Dengue NS1 Ag, Bio-Rad, Marnes-la-Coquette, France) determined by ELISA in acute serum samples. Serotyping was performed at the provincial reference laboratory.

2.2 | Data collection and study variables

Data were collected through epidemiological and clinical records and laboratory analysis performed during treatment at San Vicente de Paul Hospital’s care center.

Illness was defined as DWoWS when patients had laboratory-confirmed DENV infection and symptoms that did not fulfill the WHO definition of DWWS or SD. DWWS and SD were defined using the WHO guidelines for diagnosis. Demographic variables included sex and age; study participants aged 2-14 years were defined as children.

The clinical symptoms recorded were: fever, defined as an axial temperature greater than, or equal to 38°C; headache; retro-orbital pain: localized pain behind the eye; bipalpebral edema: abnormal fluid accumulation in the internal tissue of the eyelid; conjunctival injection: congestion and dilation of blood vessels in the sclera causing ocular redness; myalgia: pain in response to gentle pressure during physical examination; arthralgia: localized joint pain; abdominal pain: tenderness or continuous pain in physical examination; rash: red skin discoloration that disappears with pressure; itching; nausea; diarrhea: three or more loose stools per day; vomiting: three or more episodes per day; hepatomegaly: liver enlargement > 2 cm; jaundice; oligoanuria; cough; dyspnea; tachypnea: respiratory frequency greater than 20 breaths/minute; hemorrhagic syndrome: including mucosal bleeding, abundant menstruation and/or blood in urine. All clinical symptoms were considered absent or present.

Laboratory parameters were considered present or absent based of the following definitions: leukopenia-leukocyte count lower than 4000/mm³ and thrombocytopenia-platelet count lower than 150,000/mm³. The pre-existing immunity to DENV was determined by PanBio Dengue IgG Capture ELISA (Standard Diagnostics INC.), in order to distinguish between primary and secondary DENV infections.

2.3 | Statistical analysis

Data were analyzed using the chi-square test for categorical variables. Univariate logistic regression analyses were performed to investigate the association of relevant independent variables with the outcomes (eg, DWoWS vs DWWS) and odds ratios were calculated where appropriate. Multivariate analyses used a logistic regression model, adjusting odds ratios for age, sex and previous exposure to DENV. The Mann-Whitney test was used for continuous variables. P-values were calculated during regression analysis using a 2-tailed test. A P-value <0.05 was considered significant for all the tests performed. Statistical analyses were performed using Stata/SE 13.0 for Windows (StataCorp LP, College Station, TX).

2.4 | Ethics statement

This study was approved by San Vicente de Paul Hospital, Orán, Salta, Argentina, and Bioethics Committee of Facultad de Medicina, Universidad Nacional de Tucumán, Tucumán, Argentina.

3 | RESULTS

3.1 | Population characteristics

Among the 301 patients with laboratory-confirmed dengue who received care at San Vicente de Paul Hospital between February and June 2014, 37.9% presented DWWS and 62.1% DWoWS. No SD cases or deaths were reported. Patient ages ranged from 2 to 86 years with a mean (standard deviation) age of 35.5 (16.9) years (Table 1). The mean age of DWWS patients was 34.4 (17.2), while the mean age of DWoWS patients was 37.3 (17.2). The most frequent clinical manifestations were headache (94.7%), myalgia (93.0%), arthralgia (88.0%), retro-orbital pain (78.1%), and rash (54.5%). DWWS patients also exhibited significantly higher frequencies of conjunctival infection (56.1% vs 29.4%), diarrhea (32.5% vs 11.2%), cough (15.8% vs 5.9%), and dyspnea (11.4% vs 3.2%) compared to DWoWS patients. Though these symptoms are not warning signs, multivariate analyses revealed that conjunctival infection (OR = 3.02; 95% CI = 1.67–5.47; P < 0.001) and diarrhea (OR = 3.10; 95% CI = 1.48–6.49; P = 0.003) are associated with a significantly increased risk of DWWS. Among the patients who presented warning signs, 28.9% presented multiple warning signs. The most frequent warning signs were abdominal pain (27.9%) and thrombocytopenia (22.0%).

When pre-existing immunity to DENV was analyzed in the study population, we found that nearly half of patients had secondary dengue infections (47.1%; Table 1). In addition, secondary infections were not correlated to DWWS (59.3% with DWoWS vs 40.7% with DWWS; Table 1).

Interestingly, 11% of the patients with laboratory-confirmed dengue did not report fever. These patients also reported significantly
lower frequencies of headache, conjunctival injection and myalgia (Figure 2). All other symptoms were reported at frequencies similar to those reported by febrile patients (Supplementary Table S1).

### 3.2 Association of clinical manifestations and age

Several reports have described an association of dengue severity with age.6,7 In this study, no significant differences were found in the incidence of DWWS between age groups (26.5% for <15 years vs 39.3% for >15 years; Table 2), nor was there any significant correlation between the incidence of secondary infection and age groups (50.0% for <15 years vs 46.8% for >15 years; Table 2). Univariate and multivariate analyses revealed that patients over 15 years of age had a significantly increased risk of fever, retro-orbital pain, arthralgia, diarrhea, and thrombocytopenia compared to younger patients. Conversely, pediatric patients (2-14) were two times more likely to present rash than older patients (Table 2).

### TABLE 1 Demographics, constitutional, musculoskeletal, cutaneous, gastrointestinal, respiratory and hemorrhagic manifestations, and laboratory parameters of patients categorized by the WHO diagnostic guidelines

| Characteristics                     | Total n (%) | DWoWS n (%) | DWWS n (%) | P (Chi²) |
|-------------------------------------|-------------|-------------|------------|----------|
| **Demographic**                     |             |             |            |          |
| Number of patients                  | 301         | 187 (62.1)  | 114 (37.9) | -        |
| Mean age in years (StD)             | 35.5 (16.9) | 34.4 (16.6) | 37.3 (17.2) | 0.133a   |
| Age range in years                  | 2-86        | 2-78        | 6-86       | -        |
| Female (%)                          | 167 (55.5)  | 95 (50.8)   | 72 (63.2)  | 0.036    |
| **Constitutional**                  |             |             |            |          |
| Fever                               | 268 (89.0)  | 154 (82.4)  | 114 (100)  | <0.001   |
| Headache                            | 285 (94.7)  | 177 (94.7)  | 108 (94.7) | 0.975    |
| Retro-orbital pain                  | 235 (78.1)  | 140 (74.9)  | 95 (83.3)  | 0.085    |
| Bipalpebral edema                   | 6 (2.0)     | 3 (1.6)     | 3 (2.6)    | 0.536    |
| Conjunctival injection              | 119 (39.5)  | 55 (29.4)   | 64 (56.1)  | <0.001   |
| Musculoskeletal                     |             |             |            |          |
| Myalgia                             | 280 (93.0)  | 169 (90.4)  | 111 (97.4) | 0.021    |
| Arthralgia                          | 265 (88.0)  | 162 (86.6)  | 103 (90.4) | 0.335    |
| **Cutaneous**                       |             |             |            |          |
| Rash                                | 164 (54.5)  | 99 (52.9)   | 65 (57.0)  | 0.491    |
| Itching                             | 128 (42.5)  | 73 (39.0)   | 55 (48.3)  | 0.117    |
| Gastrointestinal                    |             |             |            |          |
| Nausea                              | 113 (37.5)  | 43 (23.0)   | 70 (61.4)  | <0.001   |
| Diarrhea                            | 58 (19.3)   | 21 (11.2)   | 37 (32.5)  | <0.001   |
| Vomiting                            | 43 (14.3)   | 4 (2.1)     | 39 (34.2)  | <0.001   |
| Abdominal pain                      | 84 (27.9)   | 18 (9.6)    | 66 (57.9)  | <0.001   |
| Hepatomegaly                        | 4 (1.3)     | 1 (0.5)     | 3 (2.6)    | 0.123    |
| Jaundice                            | 3 (1.0)     | 1 (0.5)     | 2 (1.8)    | 0.301    |
| Oligoanuria                         | 2 (0.7)     | 0 (0)       | 2 (1.8)    | 0.069    |
| Respiratory                         | 37 (12.3)   | 15 (8.0)    | 22 (19.3)  | 0.004    |
| Cough                               | 29 (9.6)    | 11 (5.9)    | 18 (15.8)  | 0.005    |
| Dyspnea                             | 19 (6.3)    | 6 (3.2)     | 13 (11.4)  | 0.005    |
| Tachypnea                           | 7 (2.3)     | 4 (2.1)     | 3 (2.6)    | 0.783    |
| Hemorrhagic syndrome                | 5 (1.7)     | 0 (0)       | 5 (4.4)    | 0.004    |
| **Laboratory abnormalities**        |             |             |            |          |
| Leukopenia                          | 111 (44.0)  | 54 (35.5)   | 57 (59.4)  | <0.001   |
| Thrombocytopenia                    | 54 (22.0)   | 12 (8.0)    | 42 (44.2)  | <0.001   |
| Incidence of SI                     | 140 (47.1)  | 83 (59.3)   | 57 (40.7)  | 0.435    |

DWWS, dengue with warning signs; DWoWS, dengue without warning signs; SI, secondary infection; StD, standard deviation.

aP-value was calculated using the Mann-Whitney Rank Sum test for non-categorical variables.
Clinical manifestations by sex

Previous studies have described differences in dengue presentation based on sex. Nearly 56% of the participants in our study were female and these patients had a significantly higher rate of DWWS compared to men (43.1% vs 31.3%; Table 3). Although univariate analysis showed that females had an increased risk of developing DWWS, this risk was no longer significant when adjusted for age and pre-existing immunity to DENV (Table 3). When previous exposure to DENV was studied, male and female patients were found to have similar rates of secondary infection. However, a multivariate logistic regression model showed that female patients had a significantly increased risk of rash, nausea, diarrhea, abdominal pain and leukopenia (Table 3). All other symptoms were reported at rates similar to those reported by men.

DISCUSSION

This study found variations in disease severity, clinical manifestations, and laboratory parameters between pediatric and adult patients with laboratory-confirmed DENV infections. While there is a body of published work describing a relationship between age and dengue severity, the nature of this relationship is unclear and may be complicated by confounding factors. A 3-year study of hospitalized DENV patients in Nicaragua found that infants and children aged 4-6 years were more likely to develop severe disease than adults. Similarly, a Cuban study reported that secondary DENV infections in children aged 3-15 years were 14.5 times more likely to be fatal than secondary infections in adults aged 16-39 years. Prospective school-cohort studies of DENV infections in children have reported approximately twice as many inapparent cases as symptomatic cases, and a recent review suggests that the majority of DENV infections are subclinical. The current study found that children were significantly less likely to present fever, a symptom which is frequently considered the minimum symptom in defining symptomatic infections and is critical in the WHO diagnostic guidelines.

The children in this study did not only present milder illness than adults, but they presented a distinct profile of clinical manifestations, characterized by significantly reduced risk of fever, retro-orbital pain, arthralgia, diarrhea and thrombocytopenia, and increased risk of developing rash compared to adult patients. The absence of fever in...
almost 25% of children, especially accompanied by the dramatically reduced rates of thrombocytopenia, may cause these dengue cases to be overlooked. Mild and inapparent primary DENV infection can prime a population for more severe disease in subsequent heterotypic outbreaks. In fact, longer intervals between heterotypic outbreaks have been associated with increased mortality.26,27 Furthermore, viremic patients with inapparent illness have been shown to effectively transmit DENV to mosquitoes.28 Given this background, asymptomatic, mild and non-febrile patients are vital to understanding and controlling DENV transmission and epidemic cycles in a public health context and highlight the need to monitor pediatric populations during outbreaks.

While half of children under 15 years old had secondary dengue infections, incidence of secondary infection was lower in younger children; in fact, 80% of children under 10 years old had primary infections. Given that the 1998 outbreak of DENV-2 in Salta represented the first dengue cases reported in the country in over 80 years,12 the lack of association between incidence of secondary infection and age is unsurprising. Between 1998 and 2014, DENV circulated regionally in epidemic cycles, giving older children and adults in Orán a similar lifetime risk of exposure to DENV.13,14

Virus serotype has been associated with disease severity and differential characteristic clinical manifestations.10,29,30 Consistent with our findings, previous studies have described relatively mild disease during DENV-4 outbreaks.10,31–33 A prospective 6-year study of over 2000 dengue infections found that, unlike serotypes 1-3, over half of DENV-4 infections in children were inapparent.27 One 12-year retrospective study in Thailand found that DENV-4 was half as likely as DENV-2 or DENV-3 to result in severe disease during a secondary infection.9 These findings are consistent with the results of the current study, in which none of the patients developed severe disease despite a moderate incidence of secondary infections. Interestingly, 63% of the patients reported cutaneous symptoms, which is consistent with previous DENV-4 outbreaks, but represents a higher incidence than has been reported for other serotypes.10

This study reports sex-based differences in the manifestations of DENV infection. Similar results have been reported in Mexico City,18 in French Caribbean islands,20 and in select Chinese localities.21 One study in Korea, a country in which DENV is almost exclusively imported by travelers, found significantly higher DENV incidence in men.22 Further investigation will be necessary to define whether these differences are due to physiological or to regional socio-behavioral factors.

In summary, clinical manifestations and laboratory abnormalities between pediatric and adult patients infected with DENV-4 exhibited significant differences. Variations were also noted in presentations in females compared to males. A better understanding of these differences should contribute to better assessment of emerging and re-emerging DENV infections in at-risk regions.

**ACKNOWLEDGMENTS**

This work was supported by a grant from UBS Optimus Foundation to FPP. ABB is a fellow from Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and LBT is a member of Research Career from the same institution.

**CONFLICTS OF INTEREST**

The authors have declared that no competing interests exist.

### TABLE 3 Characteristics of male and female patients and odds ratios for sex-associated symptoms

| Characteristics | Male n (%) | Female n (%) | Crude OR | Adjusted OR | Crude OR | Adjusted OR |
|-----------------|------------|--------------|----------|-------------|----------|-------------|
| Number of patients | 134 (44.5) | 167 (55.5) | - | - | - | - |
| Mean age in years (StD) | 33.7 (16.9) | 36.9 (16.7) | 0.059 | - | - | - |
| Age range in years | 2-78 | 4-86 | - | - | - | - |
| Incidence of DWWS | 42 (31.3) | 72 (43.1) | 0.036 | 1.7 | 1.03-2.67 | 0.037 | 1.8 | 0.81-4.07 |
| Incidence of SI | 59 (45.0) | 81 (48.8) | 0.520 | - | - | - |
| Symptoms | | | | | | |
| Rash | 63 (47.0) | 101 (60.5) | 0.020 | 1.7 | 1.08-2.73 | 0.020 | 1.8 | 1.10-2.82 |
| Nausea | 38 (28.4) | 75 (44.9) | 0.003 | 2.1 | 1.27-3.34 | 0.003 | 2.1 | 1.26-3.37 |
| Diarrhea | 18 (13.4) | 40 (24.0) | 0.021 | 2.0 | 1.10-3.74 | 0.023 | 2.0 | 1.05-3.63 |
| Abdominal pain | 28 (20.9) | 56 (33.5) | 0.015 | 2.2 | 1.13-3.23 | 0.016 | 1.9 | 1.11-3.19 |
| Leukopenia | 40 (34.8) | 71 (53.4) | 0.003 | 2.2 | 1.28-3.59 | 0.004 | 2.2 | 1.29-3.65 |

CI, confidence interval; DWWS, dengue with warning signs; OR, Odds ratio; SI, secondary infection; StD, standard deviation.

*p-value was calculated using the Mann-Whitney Rank Sum test for non-categorical variables.

Logistic regression model, adjusted for age and previous exposure to DENV.

P-values were calculated during univariate or multivariate analysis using a 2-tailed test.
REFERENCES

1. Forshey BM, Morrison AC, Cruz C, et al. Dengue virus serotype 4, northeastern Peru, 2008. Emerg Infect Dis. 2009;15:1815–1818.

2. The history of dengue outbreaks in the Americas. Am J Trop Med Hyg. 2012;87:584–593.

3. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496:504–507.

4. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. Geneva 2009.

5. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158:1445–1459.

6. Hammond SN, Balmaseda A, Perez L, et al. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg. 2005;73:1063–1070.

7. Nunes PC, Sampaio SA, da Costa NR, et al. Dengue severity associated with age and a new lineage of dengue virus-type 2 during an outbreak in Rio De Janeiro, Brazil. J Med Virol. 2016;88:1130–1136.

8. Talarico LB, Bugna J, Wimmenauer V, et al. T helper type 2 bias and type 17 suppression in primary dengue virus infection in infants and young children. Trans R Soc Trop Med Hyg. 2013;107:411–419.

9. Fried JR, Gibbons RV, Kalayanarooj S, et al. Age-associated differences in clinical manifestations with serotype-specific dengue virus infection with clinical manifestations. PLoS Negl Trop Dis. 2012;6:e1638.

10. Harrington LC, Scott TW, Lerdthusnee K, et al. Dispersal of the dengue vector Aedes aegypti within and between rural communities. Am J Trop Med Hyg. 2005;72:209–220.

11. Aviles G, Rangeon G, Vorndam V, et al. Dengue reemergence in Argentina. Emerg Infect Dis. 1999;5:575–578.

12. Euliarte C, de Macarrein, M., Chiarelli, G., Corallo, T., Cayre, A., Rodriguez, M. Consenso sobre enfermedades infecciosas regionales en la Argentina: Dengue. Buenos Aires: Comité Nacional de Infectología. http://www.sap.org.ar/docs/profesionales/consenos/consenso_dengue_sap2016.pdf. 2016.

13. Ministerio de Salud de la Nación. Situación del Dengue en Argentina: Parte 2010–2012: 2016/11/DENGUE-2009-2013.pdf. 2016.

14. Ministerio de Salud de la Nación. Situación de Dengue en Argentina. Boletín Epidemiológico 1851–295X. http://www.msal.gob.ar/saladesituacion/boletines_epidemiologia/pdfs/boletin-epidemiologico_dengue.pdf. 2010.

15. Ministerio de Salud de la Nación. Vigilancia del Dengue y otros arbovirus en Argentina. Boletín Integrado de Vigilancia Nº 240. http://www.msal.gob.ar/index.php/home/boletin-integrado-de-vigilancia. 2014.

16. Ministerio de Salud. Situación del dengue 2009–2013. Gobierno de Entre Ríos. http://www.enterrios.gov.ar/msalud/wp-content/uploads/2013/11/DENGUE-2009-2013.pdf. 2013.

17. Ministerio de Salud de la Nación. Situación de Dengue en Argentina: Parte de Prensa Nº 18. http://www.msal.gob.ar/images/stories/epidemiologia/parte-dengue/alerta%2018%20dengue-09-0410.pdf. 2010.

18. Dantes HG, Farfan-Ale JA, Sarti E. Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis. PLoS Negl Trop Dis. 2014;8:e3158.

19. Grange L, Simon-Loriere E, Sakuntabhai A, Gresh L, Paul R, Harris E. Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections. Front Immunol. 2014;5:280.

20. L’Azou M, Taurel AF, Flamand C, Quenel P. Recent epidemiological trends of dengue in the French territories of the Americas (2000-2012): a systematic literature review. PLoS Negl Trop Dis. 2014;8:e3235.

21. Sang S, Wang S, Lu L, BI P, Ly M, Liu Q. The epidemiological characteristics and dynamic transmission of dengue in China, 2013. PLoS Negl Trop Dis. 2016;10:e0005095.

22. Je S, Bae W, Kim J, Seok SH, Hwang ES. Epidemiological characteristics and risk factors of dengue infection in korean travelers. J Korean Med Sci. 2016;31:1863–1873.

23. Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis. 2002;6:118–124.

24. Arguello DF, Tomashek KM, Quinones L, et al. Incidence of dengue virus infection in school-aged children in Puerto Rico: a prospective seroepidemiologic study. Am J Trop Med Hyg. 2015;92:486–491.

25. Enyo TP, Chunsuttiwat S, Nisalak A, et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol. 2002;156:40–51.

26. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica. 2002;11:223–227.

27. Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7:e2357.

28. Duong V, Lambrechts L, Paul RE, et al. Asymptomatic humans transmit dengue virus to mosquitoes. Proc Natl Acad Sci USA. 2015;112:14688–14693.

29. Soo KM, Khalid B, Ching SM, Chee HY. Meta-Analysis of dengue severity during infection by different dengue virus serotypes in primary and secondary infections. PLoS ONE. 2016;11:e0154760.

30. Yung CF, Lee KS, Thein TL, et al. Dengue serotype-specific differences in clinical manifestation, laboratory parameters and risk of severe disease in adults, singapore. Am J Trop Med Hyg. 2015;92:999–1005.

31. Vaughan DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181:2–9.

32. Nisalak A, Endy TP, Nimmannitya S, et al. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg. 2003;68:191–202.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Byrne AB, Gutierrez GF, Bruno A, et al. Age-associated differences in clinical manifestations and laboratory parameters during a dengue virus type 4 outbreak in Argentina. J Med Virol. 2018;90:197–203. https://doi.org/10.1002/jmv.24952

Laura B. Talarico http://orcid.org/0000-0003-2635-474X